rs166050
From SNPedia
| Orientation | plus |
| Stabilized | plus |
| Make rs166050(A;A) |
| Make rs166050(A;G) |
| Make rs166050(G;G) |
| Reference | GRCh38 38.1/141 |
| Chromosome | 5 |
| Position | 6643734 |
| Gene | SRD5A1 |
| is a | snp |
| is | mentioned by |
| dbSNP | rs166050 |
| dbSNP (classic) | rs166050 |
| ClinGen | rs166050 |
| ebi | rs166050 |
| HLI | rs166050 |
| Exac | rs166050 |
| Gnomad | rs166050 |
| Varsome | rs166050 |
| LitVar | rs166050 |
| Map | rs166050 |
| PheGenI | rs166050 |
| Biobank | rs166050 |
| 1000 genomes | rs166050 |
| hgdp | rs166050 |
| ensembl | rs166050 |
| geneview | rs166050 |
| scholar | rs166050 |
| rs166050 | |
| pharmgkb | rs166050 |
| gwascentral | rs166050 |
| openSNP | rs166050 |
| 23andMe | rs166050 |
| SNPshot | rs166050 |
| SNPdbe | rs166050 |
| MSV3d | rs166050 |
| GWAS Ctlg | rs166050 |
| GMAF | 0.1368 |
| Max Magnitude | 0 |
| ? | (A;A) (A;G) (G;G) | 28 |
|---|---|---|
|
| ||
[PMID 23499746] SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists
[PMID 26169017] SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy
